img

Global and India Meningococcal Disease Vaccine Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and India Meningococcal Disease Vaccine Market Report & Forecast 2024-2034

Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
Market Analysis and InsightsGlobal and India Meningococcal Disease Vaccine Market
This report focuses on global and India Meningococcal Disease Vaccine market, also covers the segmentation data of other regions in regional level and county level.
The global Meningococcal Disease Vaccine revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In India the Meningococcal Disease Vaccine revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Meningococcal Disease Vaccine include AstraZeneca, Johnson & Johnson, Mylan N.V, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Sanofi and Merck & Co., Inc., etc. The global five biggest players hold a share of % in 2024.
Global Meningococcal Disease Vaccine Scope and Market Size
Meningococcal Disease Vaccine market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Meningococcal Disease Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For India market, this report focuses on the Meningococcal Disease Vaccine market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in India.



By Company


AstraZeneca
Johnson & Johnson
Mylan N.V
Teva Pharmaceutical Industries Ltd
Pfizer Inc
GlaxoSmithKline plc
Novartis AG
Sanofi
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Baxter
BIO-MED
Bio-Manguinhos
Walvax Biotechnology Co., Ltd
Segment by Type
Polysaccharide
Conjugate
Combination

Segment by Application


Infant
Child
Aldult
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Meningococcal Disease Vaccine definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Meningococcal Disease Vaccine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Meningococcal Disease Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Disease Vaccine sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 Meningococcal Disease Vaccine Product Introduction
1.2 Global Meningococcal Disease Vaccine Outlook 2018 VS 2024 VS 2034
1.2.1 Global Meningococcal Disease Vaccine Sales in US$ Million for the Year 2018-2034
1.2.2 Global Meningococcal Disease Vaccine Sales in Volume for the Year 2018-2034
1.3 India Meningococcal Disease Vaccine Outlook 2018 VS 2024 VS 2034
1.3.1 India Meningococcal Disease Vaccine Sales in US$ Million for the Year 2018-2034
1.3.2 India Meningococcal Disease Vaccine Sales in Volume for the Year 2018-2034
1.4 Meningococcal Disease Vaccine Market Size, India VS Global, 2018 VS 2024 VS 2034
1.4.1 The Market Share of India Meningococcal Disease Vaccine in Global, 2018 VS 2024 VS 2034
1.4.2 The Growth Rate of Meningococcal Disease Vaccine Market Size, India VS Global, 2018 VS 2024 VS 2034
1.5 Meningococcal Disease Vaccine Market Dynamics
1.5.1 Meningococcal Disease Vaccine Industry Trends
1.5.2 Meningococcal Disease Vaccine Market Drivers
1.5.3 Meningococcal Disease Vaccine Market Challenges
1.5.4 Meningococcal Disease Vaccine Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Meningococcal Disease Vaccine by Type
2.1 Meningococcal Disease Vaccine Market Segment by Type
2.1.1 Polysaccharide
2.1.2 Conjugate
2.1.3 Combination
2.2 Global Meningococcal Disease Vaccine Market Size by Type
2.2.1 Global Meningococcal Disease Vaccine Sales in Value, by Type (2018, 2024 & 2034)
2.2.2 Global Meningococcal Disease Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
2.2.3 Global Meningococcal Disease Vaccine Average Selling Price (ASP) by Type (2018, 2024 & 2034)
2.3 India Meningococcal Disease Vaccine Market Size by Type
2.3.1 India Meningococcal Disease Vaccine Sales in Value, by Type (2018, 2024 & 2034)
2.3.2 India Meningococcal Disease Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
2.3.3 India Meningococcal Disease Vaccine Average Selling Price (ASP) by Type (2018, 2024 & 2034)
3 Meningococcal Disease Vaccine by Application
3.1 Meningococcal Disease Vaccine Market Segment by Application
3.1.1 Infant
3.1.2 Child
3.1.3 Aldult
3.2 Global Meningococcal Disease Vaccine Market Size by Application
3.2.1 Global Meningococcal Disease Vaccine Sales in Value, by Application (2018, 2024 & 2034)
3.2.2 Global Meningococcal Disease Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 Global Meningococcal Disease Vaccine Average Selling Price (ASP) by Application (2018, 2024 & 2034)
3.3 India Meningococcal Disease Vaccine Market Size by Application
3.3.1 India Meningococcal Disease Vaccine Sales in Value, by Application (2018, 2024 & 2034)
3.3.2 India Meningococcal Disease Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 India Meningococcal Disease Vaccine Average Selling Price (ASP) by Application (2018, 2024 & 2034)
4 Global Meningococcal Disease Vaccine Competitor Landscape by Company
4.1 Global Meningococcal Disease Vaccine Market Size by Company
4.1.1 Global Key Manufacturers of Meningococcal Disease Vaccine, Ranked by Revenue (2024)
4.1.2 Global Meningococcal Disease Vaccine Revenue by Manufacturer (2018-2023)
4.1.3 Global Meningococcal Disease Vaccine Sales by Manufacturer (2018-2023)
4.1.4 Global Meningococcal Disease Vaccine Price by Manufacturer (2018-2023)
4.2 Global Meningococcal Disease Vaccine Concentration Ratio (CR)
4.2.1 Meningococcal Disease Vaccine Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Meningococcal Disease Vaccine in 2024
4.2.3 Global Meningococcal Disease Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Meningococcal Disease Vaccine, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Meningococcal Disease Vaccine, Product Offered and Application
4.5 Global Key Manufacturers of Meningococcal Disease Vaccine, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 India Meningococcal Disease Vaccine Market Size by Company
4.7.1 Key Players of Meningococcal Disease Vaccine in India, Ranked by Revenue (2024)
4.7.2 India Meningococcal Disease Vaccine Revenue by Players (2018-2023)
4.7.3 India Meningococcal Disease Vaccine Sales by Players (2018-2023)
5 Global Meningococcal Disease Vaccine Market Size by Region
5.1 Global Meningococcal Disease Vaccine Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global Meningococcal Disease Vaccine Market Size in Volume by Region (2018-2034)
5.2.1 Global Meningococcal Disease Vaccine Sales in Volume by Region: 2018-2023
5.2.2 Global Meningococcal Disease Vaccine Sales in Volume Forecast by Region (2024-2034)
5.3 Global Meningococcal Disease Vaccine Market Size in Value by Region (2018-2034)
5.3.1 Global Meningococcal Disease Vaccine Sales in Value by Region: 2018-2023
5.3.2 Global Meningococcal Disease Vaccine Sales in Value by Region: 2024-2034
6 Americas
6.1 Americas Meningococcal Disease Vaccine Market Size YoY Growth 2018-2034
6.2 Americas Meningococcal Disease Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
6.3 Americas Meningococcal Disease Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
6.4 Americas Meningococcal Disease Vaccine Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 Americas Meningococcal Disease Vaccine Sales in Value by Country (2018, 2024 & 2034)
6.4.2 Americas Meningococcal Disease Vaccine Sales in Volume by Country (2018, 2024 & 2034)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Meningococcal Disease Vaccine Market Size YoY Growth 2018-2034
7.2 EMEA Meningococcal Disease Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
7.3 EMEA Meningococcal Disease Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
7.4 EMEA Meningococcal Disease Vaccine Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 EMEA Meningococcal Disease Vaccine Sales in Value by Country (2018, 2024 & 2034)
7.4.2 EMEA Meningococcal Disease Vaccine Sales in Volume by Country (2018, 2024 & 2034)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Meningococcal Disease Vaccine Market Size YoY Growth 2018-2034
8.2 China Meningococcal Disease Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
8.3 China Meningococcal Disease Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
9 APAC
9.1 APAC Meningococcal Disease Vaccine Market Size YoY Growth 2018-2034
9.2 APAC Meningococcal Disease Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
9.3 APAC Meningococcal Disease Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
9.4 APAC Meningococcal Disease Vaccine Market Facts & Figures by Region (2018, 2024 & 2034)
9.4.1 APAC Meningococcal Disease Vaccine Sales in Value by Region (2018, 2024 & 2034)
9.4.2 APAC Meningococcal Disease Vaccine Sales in Volume by Region (2018, 2024 & 2034)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Information
10.1.2 AstraZeneca Description and Business Overview
10.1.3 AstraZeneca Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AstraZeneca Meningococcal Disease Vaccine Products Offered
10.1.5 AstraZeneca Recent Development
10.2 Johnson & Johnson
10.2.1 Johnson & Johnson Company Information
10.2.2 Johnson & Johnson Description and Business Overview
10.2.3 Johnson & Johnson Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Johnson & Johnson Meningococcal Disease Vaccine Products Offered
10.2.5 Johnson & Johnson Recent Development
10.3 Mylan N.V
10.3.1 Mylan N.V Company Information
10.3.2 Mylan N.V Description and Business Overview
10.3.3 Mylan N.V Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Mylan N.V Meningococcal Disease Vaccine Products Offered
10.3.5 Mylan N.V Recent Development
10.4 Teva Pharmaceutical Industries Ltd
10.4.1 Teva Pharmaceutical Industries Ltd Company Information
10.4.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
10.4.3 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Products Offered
10.4.5 Teva Pharmaceutical Industries Ltd Recent Development
10.5 Pfizer Inc
10.5.1 Pfizer Inc Company Information
10.5.2 Pfizer Inc Description and Business Overview
10.5.3 Pfizer Inc Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Pfizer Inc Meningococcal Disease Vaccine Products Offered
10.5.5 Pfizer Inc Recent Development
10.6 GlaxoSmithKline plc
10.6.1 GlaxoSmithKline plc Company Information
10.6.2 GlaxoSmithKline plc Description and Business Overview
10.6.3 GlaxoSmithKline plc Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.6.4 GlaxoSmithKline plc Meningococcal Disease Vaccine Products Offered
10.6.5 GlaxoSmithKline plc Recent Development
10.7 Novartis AG
10.7.1 Novartis AG Company Information
10.7.2 Novartis AG Description and Business Overview
10.7.3 Novartis AG Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Novartis AG Meningococcal Disease Vaccine Products Offered
10.7.5 Novartis AG Recent Development
10.8 Sanofi
10.8.1 Sanofi Company Information
10.8.2 Sanofi Description and Business Overview
10.8.3 Sanofi Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Sanofi Meningococcal Disease Vaccine Products Offered
10.8.5 Sanofi Recent Development
10.9 Merck & Co., Inc.
10.9.1 Merck & Co., Inc. Company Information
10.9.2 Merck & Co., Inc. Description and Business Overview
10.9.3 Merck & Co., Inc. Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Merck & Co., Inc. Meningococcal Disease Vaccine Products Offered
10.9.5 Merck & Co., Inc. Recent Development
10.10 F. Hoffmann-La Roche Ltd
10.10.1 F. Hoffmann-La Roche Ltd Company Information
10.10.2 F. Hoffmann-La Roche Ltd Description and Business Overview
10.10.3 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.10.4 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Products Offered
10.10.5 F. Hoffmann-La Roche Ltd Recent Development
10.11 Baxter
10.11.1 Baxter Company Information
10.11.2 Baxter Description and Business Overview
10.11.3 Baxter Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Baxter Meningococcal Disease Vaccine Products Offered
10.11.5 Baxter Recent Development
10.12 BIO-MED
10.12.1 BIO-MED Company Information
10.12.2 BIO-MED Description and Business Overview
10.12.3 BIO-MED Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.12.4 BIO-MED Meningococcal Disease Vaccine Products Offered
10.12.5 BIO-MED Recent Development
10.13 Bio-Manguinhos
10.13.1 Bio-Manguinhos Company Information
10.13.2 Bio-Manguinhos Description and Business Overview
10.13.3 Bio-Manguinhos Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Bio-Manguinhos Meningococcal Disease Vaccine Products Offered
10.13.5 Bio-Manguinhos Recent Development
10.14 Walvax Biotechnology Co., Ltd
10.14.1 Walvax Biotechnology Co., Ltd Company Information
10.14.2 Walvax Biotechnology Co., Ltd Description and Business Overview
10.14.3 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Products Offered
10.14.5 Walvax Biotechnology Co., Ltd Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Meningococcal Disease Vaccine Industry Chain Analysis
11.2 Meningococcal Disease Vaccine Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Meningococcal Disease Vaccine Production Mode & Process
11.4 Meningococcal Disease Vaccine Sales and Marketing
11.4.1 Meningococcal Disease Vaccine Sales Channels
11.4.2 Meningococcal Disease Vaccine Distributors
11.5 Meningococcal Disease Vaccine Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. Meningococcal Disease Vaccine CAGR in Value, India VS Global, 2018 VS 2024 VS 2034
Table 2. Meningococcal Disease Vaccine Market Trends
Table 3. Meningococcal Disease Vaccine Market Drivers
Table 4. Meningococcal Disease Vaccine Market Challenges
Table 5. Meningococcal Disease Vaccine Market Restraints
Table 6. Global Meningococcal Disease Vaccine Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. India Meningococcal Disease Vaccine Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Meningococcal Disease Vaccine Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. India Meningococcal Disease Vaccine Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Manufacturers of Meningococcal Disease Vaccine, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global Meningococcal Disease Vaccine Revenue by Manufacturer, (US$ Million), 2018-2023
Table 12. Global Meningococcal Disease Vaccine Revenue Share by Manufacturer, 2018-2023
Table 13. Global Meningococcal Disease Vaccine Sales by Manufacturer, (K Units), 2018-2023
Table 14. Global Meningococcal Disease Vaccine Sales Share by Manufacturer, 2018-2023
Table 15. Global Meningococcal Disease Vaccine Price by Manufacturer (2018-2023) & (US$/Unit)
Table 16. Global Meningococcal Disease Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Meningococcal Disease Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Meningococcal Disease Vaccine as of 2024)
Table 18. Global Key Manufacturers of Meningococcal Disease Vaccine, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of Meningococcal Disease Vaccine, Product Offered and Application
Table 20. Global Key Manufacturers of Meningococcal Disease Vaccine, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of Meningococcal Disease Vaccine in India, Ranked by Revenue (2024) & (US$ million)
Table 23. India Meningococcal Disease Vaccine Revenue by Players, (US$ Million), (2018-2023)
Table 24. India Meningococcal Disease Vaccine Revenue Share by Players, (2018-2023)
Table 25. India Meningococcal Disease Vaccine Sales by Players, (K Units), (2018-2023)
Table 26. India Meningococcal Disease Vaccine Sales Share by Players, (2018-2023)
Table 27. Global Meningococcal Disease Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 28. Global Meningococcal Disease Vaccine Sales in Volume by Region (2018-2023) & (K Units)
Table 29. Global Meningococcal Disease Vaccine Sales in Volume Forecast by Region (2024-2034) & (K Units)
Table 30. Global Meningococcal Disease Vaccine Sales in Value by Region (2018-2023) & (US$ Million)
Table 31. Global Meningococcal Disease Vaccine Sales in Value Forecast by Region (2024-2034) & (US$ Million)
Table 32. Americas Meningococcal Disease Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. Americas Meningococcal Disease Vaccine Sales in Value by Country (2018-2023) & (US$ Million)
Table 34. Americas Meningococcal Disease Vaccine Sales in Value by Country (2024-2034) & (US$ Million)
Table 35. Americas Meningococcal Disease Vaccine Sales in Volume by Country (2018-2023) & (K Units)
Table 36. Americas Meningococcal Disease Vaccine Sales in Volume by Country (2024-2034) & (K Units)
Table 37. EMEA Meningococcal Disease Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. EMEA Meningococcal Disease Vaccine Sales in Value by Country (2018-2023) & (US$ Million)
Table 39. EMEA Meningococcal Disease Vaccine Sales in Value by Country (2024-2034) & (US$ Million)
Table 40. EMEA Meningococcal Disease Vaccine Sales in Volume by Country (2018-2023) & (K Units)
Table 41. EMEA Meningococcal Disease Vaccine Sales in Volume by Country (2024-2034) & (K Units)
Table 42. APAC Meningococcal Disease Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. APAC Meningococcal Disease Vaccine Sales in Value by Country (2018-2023) & (US$ Million)
Table 44. APAC Meningococcal Disease Vaccine Sales in Value by Country (2024-2034) & (US$ Million)
Table 45. APAC Meningococcal Disease Vaccine Sales in Volume by Country (2018-2023) & (K Units)
Table 46. APAC Meningococcal Disease Vaccine Sales in Volume by Country (2024-2034) & (K Units)
Table 47. AstraZeneca Company Information
Table 48. AstraZeneca Description and Business Overview
Table 49. AstraZeneca Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 50. AstraZeneca Meningococcal Disease Vaccine Product
Table 51. AstraZeneca Recent Development
Table 52. Johnson & Johnson Company Information
Table 53. Johnson & Johnson Description and Business Overview
Table 54. Johnson & Johnson Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 55. Johnson & Johnson Meningococcal Disease Vaccine Product
Table 56. Johnson & Johnson Recent Development
Table 57. Mylan N.V Company Information
Table 58. Mylan N.V Description and Business Overview
Table 59. Mylan N.V Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 60. Mylan N.V Meningococcal Disease Vaccine Product
Table 61. Mylan N.V Recent Development
Table 62. Teva Pharmaceutical Industries Ltd Company Information
Table 63. Teva Pharmaceutical Industries Ltd Description and Business Overview
Table 64. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 65. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product
Table 66. Teva Pharmaceutical Industries Ltd Recent Development
Table 67. Pfizer Inc Company Information
Table 68. Pfizer Inc Description and Business Overview
Table 69. Pfizer Inc Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 70. Pfizer Inc Meningococcal Disease Vaccine Product
Table 71. Pfizer Inc Recent Development
Table 72. GlaxoSmithKline plc Company Information
Table 73. GlaxoSmithKline plc Description and Business Overview
Table 74. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 75. GlaxoSmithKline plc Meningococcal Disease Vaccine Product
Table 76. GlaxoSmithKline plc Recent Development
Table 77. Novartis AG Company Information
Table 78. Novartis AG Description and Business Overview
Table 79. Novartis AG Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 80. Novartis AG Meningococcal Disease Vaccine Product
Table 81. Novartis AG Recent Development
Table 82. Sanofi Company Information
Table 83. Sanofi Description and Business Overview
Table 84. Sanofi Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Sanofi Meningococcal Disease Vaccine Product
Table 86. Sanofi Recent Development
Table 87. Merck & Co., Inc. Company Information
Table 88. Merck & Co., Inc. Description and Business Overview
Table 89. Merck & Co., Inc. Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Merck & Co., Inc. Meningococcal Disease Vaccine Product
Table 91. Merck & Co., Inc. Recent Development
Table 92. F. Hoffmann-La Roche Ltd Company Information
Table 93. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 94. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product
Table 96. F. Hoffmann-La Roche Ltd Recent Development
Table 97. Baxter Company Information
Table 98. Baxter Description and Business Overview
Table 99. Baxter Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. Baxter Meningococcal Disease Vaccine Product
Table 101. Baxter Recent Development
Table 102. BIO-MED Company Information
Table 103. BIO-MED Description and Business Overview
Table 104. BIO-MED Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. BIO-MED Meningococcal Disease Vaccine Product
Table 106. BIO-MED Recent Development
Table 107. Bio-Manguinhos Company Information
Table 108. Bio-Manguinhos Description and Business Overview
Table 109. Bio-Manguinhos Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Bio-Manguinhos Meningococcal Disease Vaccine Product
Table 111. Bio-Manguinhos Recent Development
Table 112. Walvax Biotechnology Co., Ltd Company Information
Table 113. Walvax Biotechnology Co., Ltd Description and Business Overview
Table 114. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product
Table 116. Walvax Biotechnology Co., Ltd Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Meningococcal Disease Vaccine Customers List
Table 120. Meningococcal Disease Vaccine Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Meningococcal Disease Vaccine Product Picture
Figure 2. Global Meningococcal Disease Vaccine Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global Meningococcal Disease Vaccine Market Size 2018-2034 (US$ Million)
Figure 4. Global Meningococcal Disease Vaccine Sales 2018-2034 (K Units)
Figure 5. India Meningococcal Disease Vaccine Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 6. India Meningococcal Disease Vaccine Market Size 2018-2034 (US$ Million)
Figure 7. India Meningococcal Disease Vaccine Sales 2018-2034 (K Units)
Figure 8. India Meningococcal Disease Vaccine Market Share in Global, in Value (US$ Million) 2018-2034
Figure 9. India Meningococcal Disease Vaccine Market Share in Global, in Volume (K Units) 2018-2034
Figure 10. Meningococcal Disease Vaccine Report Years Considered
Figure 11. Product Picture of Polysaccharide
Figure 12. Product Picture of Conjugate
Figure 13. Product Picture of Combination
Figure 14. Global Meningococcal Disease Vaccine Market Share by Type in 2024 & 2034
Figure 15. Global Meningococcal Disease Vaccine Sales in Value by Type (2018-2034) & (US$ Million)
Figure 16. Global Meningococcal Disease Vaccine Sales Market Share in Value by Type (2018-2034)
Figure 17. Global Meningococcal Disease Vaccine Sales by Type (2018-2034) & (K Units)
Figure 18. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 19. Global Meningococcal Disease Vaccine Price by Type (2018-2034) & (US$/Unit)
Figure 20. India Meningococcal Disease Vaccine Market Share by Type in 2024 & 2034
Figure 21. India Meningococcal Disease Vaccine Sales in Value by Type (2018-2034) & (US$ Million)
Figure 22. India Meningococcal Disease Vaccine Sales Market Share in Value by Type (2018-2034)
Figure 23. India Meningococcal Disease Vaccine Sales by Type (2018-2034) & (K Units)
Figure 24. India Meningococcal Disease Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 25. India Meningococcal Disease Vaccine Price by Type (2018-2034) & (US$/Unit)
Figure 26. Product Picture of Infant
Figure 27. Product Picture of Child
Figure 28. Product Picture of Aldult
Figure 29. Global Meningococcal Disease Vaccine Market Share by Application in 2024 & 2034
Figure 30. Global Meningococcal Disease Vaccine Sales in Value by Application (2018-2034) & (US$ Million)
Figure 31. Global Meningococcal Disease Vaccine Sales Market Share in Value by Application (2018-2034)
Figure 32. Global Meningococcal Disease Vaccine Sales by Application (2018-2034) & (K Units)
Figure 33. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 34. Global Meningococcal Disease Vaccine Price by Application (2018-2034) & (US$/Unit)
Figure 35. India Meningococcal Disease Vaccine Market Share by Application in 2024 & 2034
Figure 36. India Meningococcal Disease Vaccine Sales in Value by Application (2018-2034) & (US$ Million)
Figure 37. India Meningococcal Disease Vaccine Sales Market Share in Value by Application (2018-2034)
Figure 38. India Meningococcal Disease Vaccine Sales by Application (2018-2034) & (K Units)
Figure 39. India Meningococcal Disease Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 40. India Meningococcal Disease Vaccine Price by Application (2018-2034) & (US$/Unit)
Figure 41. Americas Meningococcal Disease Vaccine Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 42. Americas Meningococcal Disease Vaccine Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 43. Americas Meningococcal Disease Vaccine Sales by Type (2018-2034) & (K Units)
Figure 44. Americas Meningococcal Disease Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 45. Americas Meningococcal Disease Vaccine Sales by Application (2018-2034) & (K Units)
Figure 46. Americas Meningococcal Disease Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 47. United States Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 48. Canada Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 49. Mexico Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 50. Brazil Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 51. EMEA Meningococcal Disease Vaccine Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 52. EMEA Meningococcal Disease Vaccine Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 53. EMEA Meningococcal Disease Vaccine Sales by Type (2018-2034) & (K Units)
Figure 54. EMEA Meningococcal Disease Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 55. EMEA Meningococcal Disease Vaccine Sales by Application (2018-2034) & (K Units)
Figure 56. EMEA Meningococcal Disease Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 57. Europe Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 58. Middle East Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 59. Africa Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 60. China Meningococcal Disease Vaccine Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 61. China Meningococcal Disease Vaccine Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 62. China Meningococcal Disease Vaccine Sales by Type (2018-2034) & (K Units)
Figure 63. China Meningococcal Disease Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 64. China Meningococcal Disease Vaccine Sales by Application (2018-2034) & (K Units)
Figure 65. China Meningococcal Disease Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 66. APAC Meningococcal Disease Vaccine Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 67. APAC Meningococcal Disease Vaccine Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 68. APAC Meningococcal Disease Vaccine Sales by Type (2018-2034) & (K Units)
Figure 69. APAC Meningococcal Disease Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 70. APAC Meningococcal Disease Vaccine Sales by Application (2018-2034) & (K Units)
Figure 71. APAC Meningococcal Disease Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 72. Japan Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 73. South Korea Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 74. China Taiwan Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 76. India Meningococcal Disease Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 77. Meningococcal Disease Vaccine Value Chain
Figure 78. Meningococcal Disease Vaccine Production Process
Figure 79. Channels of Distribution
Figure 80. Distributors Profiles
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed